Bayer Completes Phase-II On BAY 94-9172 For Alzheimer’s Disease
Bayer Schering Pharma has completed its first global phase-II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK). The study used positron emission tomography (PET) in patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.